FILTER

FILTERED INTERVIEW RESULTS

Dr. Trevor P. Castor

PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.

Doug Giordano

SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.

Michael Gladstone

PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.

David DeJean

SENIOR VICE PRESIDENT, SYSTECH INTERNATIONAL
Systech International is a technology leader in supply chain safety and brand protection.

Robert Foster

CEO, HEPION PHARMACEUTICALS
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease.

Daniel J O’Connor

PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using its plasmid DNA delivery platform.

Peter Meath

MANAGING DIRECTOR & CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, J.P. MORGAN COMMERCIAL BANKING
.P.Morgan explains the complete ecosystem that it has developed for life science companies, aiming to serve their needs throughout their entire life cycle, from opening a bank account on Day 1, to expanding internationally and through a potential IPO and beyond.

John Patrick Oroho

EXECUTIVE VICE PRESIDENT AND CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES, LLC
Porzio Life Sciences, LLC (PorzioLS) is a provider of compliance operations products and services for the life sciences industry, and a wholly‐owned subsidiary of the Porzio, Bromberg & Newman, P.C. law firm.

Ciara Kennedy

PRESIDENT AND CEO, AMPLYX PHARMACEUTICALS
Amplyx Pharmaceuticals has a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients.

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Biopharmaceuticals 2020

PARTNER EVENTS